Adrenergic nerves activate an angio-metabolic switch in prostate cancer

Nerves closely associate with blood vessels and help to pattern the vasculature during development. Recent work suggests that newly formed nerve fibers may regulate the tumor microenvironment, but their exact functions are unclear. Studying mouse models of prostate cancer, we show that endothelial β...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 358; no. 6361; pp. 321 - 326
Main Authors Zahalka, Ali H., Arnal-Estapé, Anna, Maryanovich, Maria, Nakahara, Fumio, Cruz, Cristian D., Finley, Lydia W. S., Frenette, Paul S.
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 20.10.2017
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Nerves closely associate with blood vessels and help to pattern the vasculature during development. Recent work suggests that newly formed nerve fibers may regulate the tumor microenvironment, but their exact functions are unclear. Studying mouse models of prostate cancer, we show that endothelial β-adrenergic receptor signaling via adrenergic nerve–derived noradrenaline in the prostate stroma is critical for activation of an angiogenic switch that fuels exponential tumor growth. Mechanistically, this occurs through alteration of endothelial cell metabolism. Endothelial cells typically rely on aerobic glycolysis for angiogenesis. We found that the loss of endothelial Adrb2, the gene encoding the β₂-adrenergic receptor, leads to inhibition of angiogenesis through enhancement of endothelial oxidative phosphorylation. Codeletion of Adrb2 and Cox10, a gene encoding a cytochrome IV oxidase assembly factor, prevented the metabolic shift induced by Adrb2 deletion and rescued prostate cancer progression. This cross-talk between nerves and endothelial metabolism could potentially be targeted as an anticancer therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aah5072